MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Myriad Genetics is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive company-specific catalysts, but the current setup is mixed: technicals are overbought, analysts are only Hold with a lower target, and there is no strong proprietary buy signal. I would not chase it at this price.
MYGN closed at 5.98, essentially flat on the day, with the stock sitting just above the first resistance area near 5.956 and below the next resistance at 6.364. The MACD histogram is positive at 0.151, which supports short-term momentum, but it is contracting, suggesting that upside strength may be fading. RSI_6 is 81.487, which is clearly overbought. Moving averages are converging, indicating a lack of strong trend conviction. Overall, the chart shows a short-term bounce, but it looks extended and not ideal for a fresh long-term entry.
["New data on the Prolaris biopsy test showed significant prognostic value beyond conventional risk categories, which supports the product story.", "Expanded availability of Precise MRD for cancer patients helped lift the shares recently, showing event-driven momentum.", "Management appears confident in the 2026 outlook, supported by HCT momentum, a refreshed sales force, and new product launches."]
["TD Cowen cut its price target to $6 from $7 and kept a Hold rating, signaling limited upside from current levels.", "The latest quarter was described as a bit light, and revenue remains under pressure.", "The stock is technically overbought, which makes immediate upside less attractive for a new buyer.", "Hedge fund activity and insider activity are both neutral, so there is no strong smart-money confirmation.", "No recent politician or congress trading activity was reported, so there is no influential buying signal."]
No detailed financial snapshot was available for the latest quarter, but the commentary indicates the quarter was somewhat light, with declining revenues and an expected loss. The latest quarter season referenced by analysts is Q1 2026, and while management reiterated 2026 guidance, it depends on a steep second-half acceleration. That points to potential future improvement, but the current financial trend is not yet strong enough to justify an aggressive long-term buy.
Recent analyst tone is cautious. TD Cowen lowered its price target to $6 from $7 and maintained a Hold rating. The pros view is that management believes 2026 can improve through HCT momentum and new product launches. The cons view is that Q1 was light, revenues are declining, and the updated target is only marginally above the current price, implying limited upside. Overall, Wall Street is neutral to mildly cautious rather than bullish.
